Huanji Xu
- Cancer Research top 5%
- Cancer, Lipids, and Metabolism 8
- Biological Psychiatry top 10%
-
- Ferroptosis and cancer prognosis 5
-
- PI3K/AKT/mTOR signaling in cancer 5
- Melanoma and MAPK Pathways 4
-
- Cancer, Stress, Anesthesia, and Immune Response 5
-
- Cholesterol and Lipid Metabolism 5
-
- Autophagy in Disease and Therapy 5
-
- Hippo pathway signaling and YAP/TAZ 5
- Journals
- Scientific Reports (1 paper)The FASEB Journal (1 paper)Biochemical and Biophysical Research Communications (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Huanji Xu
44 papers receiving 1.2k citations
Hit Papers
Peers
Comparison fields: 5 of 97
- Cancer Research 495
- Biological Psychiatry 32
- Pulmonary and Respiratory Medicine 371
- Molecular Biology 661
- Oncology 225
Countries citing papers authored by Huanji Xu
This map shows the geographic impact of Huanji Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huanji Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huanji Xu more than expected).
Fields of papers citing papers by Huanji Xu
This network shows the impact of papers produced by Huanji Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huanji Xu. The network helps show where Huanji Xu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Huanji Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 5 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 21 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 9 | |
| 7 | 2022 | 16 | |
| 8 | 2022 | 3 | |
| 9 | 2021 | 55 | |
| 10 | 2021 | 34 | |
| 11 | 2021 | 22 | |
| 12 | Ferroptosis in the tumor microenvironment: perspectives for immunotherapybreakdown → | 2021 | 230 |
| 13 | Cholesterol metabolism: New functions and therapeutic approaches in cancerbreakdown → | 2020 | 253 |
| 14 | 2020 | 19 | |
| 15 | 2019 | 35 | |
| 16 | 2019 | 1 | |
| 17 | 2019 | 14 | |
| 18 | 2019 | 25 | |
| 19 | 2018 | 26 | |
| 20 | 2017 | 85 |
About Huanji Xu
Huanji Xu is a scholar working on Biological Psychiatry, Cancer Research and Cell Biology, having authored 45 papers that have together received 1.2k indexed citations. Recurring topics across this work include Cancer, Lipids, and Metabolism (8 papers), Cancer, Stress, Anesthesia, and Immune Response (5 papers), Ferroptosis and cancer prognosis (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Cholesterol and Lipid Metabolism (5 papers), Autophagy in Disease and Therapy (5 papers), Hippo pathway signaling and YAP/TAZ (5 papers) and Melanoma and MAPK Pathways (4 papers). The work is most often cited by research in Cancer Research (495 citations), Biological Psychiatry (32 citations) and Pulmonary and Respiratory Medicine (371 citations). Huanji Xu has collaborated with scholars based in China and United States. Frequent co-authors include Qiulin Tang, Hongwei Xia, Feng Bi, Sheng Zhou, Feng Bi, Di Ye, Hongying Zhang, Chenliang Zhang, Qiyong Gong and Jian Yang. Their work appears in journals such as Scientific Reports, The FASEB Journal and Biochemical and Biophysical Research Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.